Skip to content

#罕见病

Today 0 items
Oct 15Thu
  1. biopharmadive.com56

    FDA ‘reset’ continues with new plan for reviewing rare disease drugs

    The FDA on Oct. 14, 2026 unveiled the "Rare Disease Framework Initiative," a plan to "reimagine" how it regulates rare disease therapies by setting standards for individual conditions rather than a one-size-fits-all approach. The initiative will review policies from preclinical engagement through post-marketing requirements, seek patient and expert input, and, per Bloomberg News, targets initial recommendations for February. The agency will take feedback at an Oct. 28 meeting on its Silver Spring, Maryland campus.

  2. biospace.com62

    FDA's latest rare disease framework seeks to prioritize consistency in flexibility

    The FDA launched its Rare Disease Framework Initiative to standardize how clinical trial requirements are applied across rare diseases while tailoring evidence expectations to what small patient populations can realistically generate. Only 5% of an estimated 10,000 rare conditions affecting 30 million Americans have an FDA-approved treatment. The framework builds on programs such as the Rare Disease Innovation Hub, CDER's ARC program and the RDEA pilot, and follows the November 2025 plausible mechanism pathway. The FDA will hold a meeting on Oct. 28 to gather feedback from patients, advocates and industry.

    Why it matters: FDA policy shift sets consistent rules for rare disease drug development, a core issue for sponsors of gene and cell therapies.

  3. medicalxpress.com53

    Expanded genetic testing and early transplant referrals anchor new myelofibrosis care recommendations

    The American Society of Hematology has issued 10 evidence-based recommendations for managing myelofibrosis, a rare blood cancer affecting up to six per 100,000 people, published in Blood Advances. The guidelines call for extended molecular testing at diagnosis, early transplant consultation for higher-risk patients responding to JAK inhibitors, appropriate JAK inhibitor use by risk level, anemia management strategies, and low-dose aspirin for patients with the JAK2 V617F mutation. Panel chair Brady Stein says the panel hopes the questions posed will set a future research agenda on treatment prediction, anemia and transplant timing.

    Why it matters: First ASH guidelines covering myelofibrosis care decisions from testing to transplant will shape clinical practice in a rare cancer.

  4. fda.gov53

    FDA Rare Disease Innovation Hub

    The FDA Rare Disease Innovation Hub released its Strategic Agenda on February 2, 2026, setting out its goals and priorities for the coming year for the rare disease community. The Hub, co-led by the directors of CBER, CDER and CDRH with the Oncology Center of Excellence and Office of Orphan Products Development, will focus on products for smaller populations and diseases with variable, poorly understood natural history. It has scheduled public meetings for October 16 and October 28, 2026.

  5. fda.gov51

    FDA Rare Disease Framework Initiative Public Meeting - 10/28/2026

    The FDA, with the Reagan-Udall Foundation for the FDA, will hold a hybrid public meeting on October 28, 2026, from 1:00 p.m. to 5:00 p.m. ET at the FDA White Oak Campus in Silver Spring, Maryland, and via Zoom. The meeting seeks input from patients, advocates, sponsors and others on the FDA's Rare Disease Framework Initiative, which aims to build a fit-for-purpose approach to rare disease drug development in small patient populations. Public remarks will inform the agency's work on the Framework, with input sought on fit-for-purpose review, regulatory predictability, external engagement and CMC considerations.

  6. fda.gov62

    FDA Launches the Rare Disease Framework Initiative to Develop a Holistic, Fit-For-Purpose Framework for Rare Disease Drug Development

    The FDA launched the Rare Disease Framework Initiative to build a fit-for-purpose framework for developing drugs and biologics for rare diseases, outlined in a new white paper dated October 14, 2026. The initiative, led by the Rare Disease Innovation Hub with the Commissioner's office, CBER and CDER, will tailor regulatory requirements to small patient populations, with only about 5% of rare conditions having an FDA-approved treatment. A public meeting on October 28 at the White Oak campus, facilitated by the Reagan-Udall Foundation, opens a feedback process that will inform new guidance, regulation revisions, training and organizational changes.

  7. fda.gov63

    Rare Disease Framework

    The FDA, with the Reagan-Udall Foundation for the FDA, will hold a hybrid public meeting on October 28, 2026, to gather input on its Rare Disease Framework Initiative, which aims to reimagine the agency's approach to rare disease drug development and review. The framework would tailor regulatory advice and decision-making to the evidence reasonably attainable for each disease, embed the patient voice at defined milestones, leverage external expertise, and apply risk-based approaches to manufacturing review and inspections. Changes could come through regulations, guidance documents and internal processes; FDA set out its aims in a white paper released October 14, 2026.

    Why it matters: FDA's rare disease development and review overhaul could change regulatory expectations for sponsors of orphan drugs.

Oct 13Tue
  1. nature.com80

    FDA nod for rare neurology drug

    The FDA has approved Ionis Pharmaceuticals' Zanvastro (zilganersen), the first disease-modifying drug for Alexander disease, a rare progressive and often fatal neurological condition affecting about one person per 1-3 million. The antisense oligonucleotide targets RNA encoding glial fibrillary acidic protein (GFAP), reducing its overproduction in astrocytes, where excess GFAP forms clumps that disrupt myelination. Patients suffer impaired motor function, seizures, intellectual disability and developmental delays.

    Why it matters: First disease-modifying therapy approved for a rare, previously untreatable neurological condition.

Oct 9Fri
  1. biocentury.com40

    FDA’s CDER approved nine NMEs in September

    FDA's CDER approved nine new molecular entities in September 2026, its highest monthly total of the year, lifting the year-to-date count to 45, one short of the full-year 2025 figure. Six of the nine approvals were treatments for rare diseases, including first approved therapies for MCT8 deficiency and Alexander disease. Companies behind the approvals include Abbvie, AstraZeneca, Bristol Myers Squibb, Curium Pharma, Egetis Therapeutics, Eisai and Elevar Therapeutics.

Oct 8Thu
  1. medicalxpress.com61

    NHS labs fail to share data vital for diagnosis and care of rare diseases, investigation finds

    A BMJ investigation finds that three of England's seven NHS Genomics Laboratory Hubs, those covering South East, South West, and North East and Yorkshire, are not routinely submitting genetic variants to public databases such as ClinVar, as required since 2024 under ACGS guidance. Even hubs that submit face significant backlogs. The labs cite staffing, technology and infrastructure gaps and say they plan routine submissions this year, while experts warn rare disease patients are missing out on diagnosis and care.

    Why it matters: Non-sharing of NHS variant data limits rare disease diagnosis and public value of genomic testing.

Oct 7Wed
  1. fda.gov40

    Rare Disease Drug Approvals

    FDA's CDER lists recent rare disease drug approvals on its Accelerating Rare Disease Cures Program page. In 2026 alone these include Camzyos for an inherited heart condition in children, Emcitate for MCT8 deficiency, Isembyld for muscle loss in spinal muscular atrophy, and Zanvastro for Alexander Disease, among others. The list spans 2021 to 2026 and links to the underlying FDA news releases.

Oct 6Tue
  1. biospace.com48

    FDA extends review of Novo’s hemophilia A drug, citing manufacturing issues

    The FDA has extended its review of Novo's denecimig, an investigational bispecific antibody and next-gen factor VIII mimetic for prophylactic treatment of hemophilia A, citing ongoing facility remediation activities at an unnamed manufacturing site. The agency flagged no efficacy or safety deficiencies, and Novo, which submitted the drug in September 2025 with a decision originally slated for the third quarter, says it is addressing the FDA's requests and still preparing for a 2027 launch in adults and children. The FDA has not shared a new review timeline, and European regulators are also evaluating the programme.

    Why it matters: FDA manufacturing delay affects a potential hemophilia A approval and ties into Novo's broader Catalent-related quality problems.

  2. fda.gov40

    Rare Disease News & Events

    The FDA's ARC Program reviewed its 2025 rare disease work, reporting more than 30 public speaking engagements, 57-plus workshops, consults or meetings supporting rare disease drug development, and 45,000 rare disease news subscribers served. CDER approved 46 novel drugs in 2025, with 32 approved first in the U.S. and 23 carrying orphan drug designation. In FY25 the Office of Orphan Products Development granted 450 of 657 original orphan-drug designation requests, and public workshops on rare disease data sharing and neonatal product development are scheduled or archived for 2026.

Oct 5Mon
  1. nature.com73

    Gene therapy for rare lysosomal storage disorder nabs FDA approval

    The FDA has approved Ultragenyx Pharmaceutical's gene therapy rebisufligene etisparvovec (Fayuvi) for paediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A. It is the first FDA-approved treatment option for this rare neurodegenerative lysosomal storage disorder.

    Why it matters: First FDA-approved therapy for a rare neurodegenerative lysosomal storage disorder.

Sep 30Wed
  1. biospace.com45

    Atara, Pierre Fabre resubmit twice-rebuffed cell therapy after FDA flips again

    Atara Biotherapeutics and Pierre Fabre Pharmaceuticals have resubmitted the BLA for Ebvallo (tabelecleucel) to treat EBV-positive posttransplant lymphoproliferative disease in patients 2 years and older, after two complete response letters, the second in January. The FDA reversed course in May, agreeing a single-arm study with an appropriate historical control could support approval. The resubmission adds patients and longer follow-up from the Phase 3 ALLELE trial plus expanded access, separate study and European commercial data; a Class 2 resubmission could carry a March 29, 2027 action date, and Atara is eligible for a $31 million milestone on approval.

  2. biospace.com45

    Milestone Sanfilippo nod helps Ultragenyx regroup after tough Angelman defeat

    The FDA approved Ultragenyx's Fayuvi for Sanfilippo syndrome type A, the first-ever treatment for that condition, shortly after approving the company's first gene therapy, Genglycos, for glycogen storage disease type Ia; each approval came with a priority review voucher worth as much as $200 million. The wins follow the Phase 3 Asire trial failure of apazunersen in Angelman syndrome, which cut the stock nearly 50%, and a January failure of setrusumab in osteogenesis imperfecta that erased $1 billion in value. CEO Emil Kakkis says Ultragenyx will implement significant expense reductions while keeping the setrusumab program and awaiting an upcoming Angelman readout.

    Why it matters: Two rare-disease approvals including a first Sanfilippo treatment come amid Phase 3 failures forcing cost cuts at Ultragenyx.

  4. endpoints.news50

    Egetis Therapeutics' Emcitate cleared by FDA for rare X-linked genetic disease

    The FDA has cleared Egetis Therapeutics' Emcitate, a drug for a rare X-linked genetic disease that shortens life expectancy to 35 years. Egetis secured the US approval on Monday. Next steps for the company's commercialization of Emcitate were not disclosed.

    Why it matters: First FDA approval of a therapy for a rare X-linked disease with life expectancy of 35 years.

Sep 29Tue
  1. fda.gov65

    FDA Approves First Treatment for MCT8 Deficiency

    The FDA approved Emcitate (tiratricol) oral suspension, from Egetis Therapeutics US Inc., for peripheral thyrotoxicosis in patients with MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome. It is the first FDA-approved therapy for the rare genetic disease, which mainly affects males. Evidence came from a randomized placebo-controlled trial (NCT05579327) and a longer-term open-label study spanning infants to adults. The once-daily liquid can be given by mouth or feeding tube.

    Why it matters: First FDA-approved therapy for MCT8 deficiency, a rare genetic disease with no prior treatment option.

Sep 28Mon
  1. biospace.com63

    FDA nod for Mirum’s Atebrioz makes 3 options for ultra-rare bone disease

    The FDA approved Mirum Pharmaceuticals' zilurgisertib, to be marketed as Atebrioz, for fibrodysplasia ossificans progressiva in patients 12 years and older, making it the third FOP treatment after Ipsen's Sohonos (August 2023) and Regeneron's Pasatru. The once-daily ALK2 inhibitor, which Mirum gained full ownership of in April after licensing from Incyte, showed an 81% reduction in new lesion volume and 99% reduction in total volume versus placebo at 24 weeks in the Phase 2 PROGRESS study, with effects maintained through week 48. Mirum is now conducting trials in children as young as 2 years.

    Why it matters: FDA approval of a third FOP drug in five weeks changes treatment options in a disease that had no therapies for decades.

Sep 19Sat
  1. BioCentury69

    Ultragenyx wins first approval for MPS IIIA, closing a bumpy four-year path

    FDA granted Ultragenyx traditional approval for rebisufligene etisparvovec, now Fayuvi, the first treatment for Sanfilippo syndrome Type A (MPS IIIA). CBER approved the gene therapy on clinical evidence that treated children maintained or improved cognitive function versus an untreated natural-history cohort, rather than on CSF heparan sulfate as a surrogate endpoint. The outcome exceeds the accelerated approval Ultragenyx had sought in its original application and resubmission, while CBER's biomarker stance remains unresolved.

    Why it matters: First therapy approved for MPS IIIA and an FDA traditional approval relying on external controls.

Sep 18Fri
  1. ema.europa.eu40

    Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2026

    The EMA's CHMP recommended 12 new medicines for approval at its September 2026 meeting, including Frehemgo (denecimig) for bleeding prophylaxis in haemophilia A, Gevalka (ensartinib) for ALK-positive advanced non-small cell lung cancer, and Povofortay (povorcitinib), the first oral daily treatment for adults with hidradenitis suppurativa refractory or intolerant to anti-TNF therapy. Two initial marketing authorisation applications were withdrawn, Isembyld for 5q spinal muscular atrophy and Zinmyleo for chemotherapy-induced myelosuppression. Re-examinations of negative opinions for Kemsu, Meplyffa and Qezzaqar will follow once grounds are received.

  3. fda.gov70

    FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type A

    The FDA approved Fayuvi (rebisufligene etisparvovec-hopf), a one-time intravenous AAV9 gene therapy from Ultragenyx Pharmaceutical, as the first treatment for pediatric patients with mucopolysaccharidosis type IIIA, or Sanfilippo syndrome type A. In an open-label, single-arm multicenter study, treated patients aged 2 to 5 maintained or improved cognitive scores versus an untreated historical control. Patients receive corticosteroids from one day before infusion through at least eight weeks after, with warnings including thrombotic microangiopathy.

    Why it matters: First FDA-approved therapy for a rare pediatric neurodegenerative disease with no prior disease-altering treatment.

Sep 12Sat
  1. statnews.com72

    STAT+: Scholar Rock wins FDA approval for first drug to target SMA muscle loss

    The FDA has approved Scholar Rock's Isembyld, the first therapy to target muscle loss in spinal muscular atrophy, for adults and children aged 2 and older already receiving SMA therapies that target SMN2. In a late-stage trial, Isembyld combined with an SMN2-targeting drug improved young patients' motor skills over a year while placebo recipients declined, a statistically significant difference. Approval was granted on Friday.

    Why it matters: First FDA-approved drug targeting SMA muscle loss adds a new mechanism to existing SMN2 therapy.

Sep 4Fri
  1. fiercepharma.com43

    Ionis’ ‘breakthrough’ Alexander disease approval establishes pillar of rare disease pipeline

    The FDA has approved Ionis' drug for Alexander disease, a rare and often fatal neurological condition, giving the company a pillar for its rare disease pipeline. The approval follows diagnoses like that of Elise Pearson, whose seizures and MRI changes led to a genetic confirmation of the disease at under three years old. Ionis now has an approved therapy in a indication with no prior treatment named in the news.

    Why it matters: Ionis gains an approval in Alexander disease, adding an approved product to its rare disease pipeline.

  2. fiercebiotech.com49

    Ionis’ ‘breakthrough’ Alexander disease approval establishes pillar of rare disease pipeline

    Ionis has secured approval for its Alexander disease treatment, a decision the company sees as establishing a pillar of its rare disease pipeline. Alexander disease is a rare genetic condition; in the case described, a toddler diagnosed after seizures and MRI changes had no prior treatment option indicated. The approval positions Ionis to build further in rare diseases.

    Why it matters: Regulatory approval for a rare genetic brain disease with no prior treatment, from Ionis' rare disease pipeline.

  3. statnews.com60

    STAT+: Ionis wins FDA approval for first drug for Alexander disease, a rare and deadly neurological disorder

    The FDA approved Ionis Pharmaceuticals' Zanvastro as the first disease-modifying therapy for Alexander disease, a rare and deadly neurological condition, for use in children and adults. In a pivotal trial, walking speed stayed stable in treated patients while the control group declined 33%, and the data hinted that treating young children may improve motor function. The drug was generally safe, with serious adverse events more common in the control group.

    Why it matters: First approved therapy for a rare, fatal neurological disorder is direct news for clinicians and industry readers.

  4. fda.gov70

    FDA Approves First Drug to Treat Alexander Disease

    The FDA has approved Zanvastro (zilganersen) injection from Ionis Pharmaceuticals for Alexander disease in pediatric and adult patients, the first treatment for this rare neurological disorder and the first to target the abnormal GFAP protein buildup that drives it. Efficacy rested on a 49-patient randomized controlled study plus a 4-patient open-label substudy in infants under 2, with treated patients aged 5 and older showing better walking speed at 61 weeks. The antisense oligonucleotide is injected into the spinal canal every three months.

    Why it matters: First-ever FDA approval for a rare neurodegenerative disease, granted to Ionis Pharmaceuticals.

Sep 1Tue
  1. gov.uk78

    MHRA concludes review of Avacopan Vifor following reassessment of benefit-risk balance

    The MHRA will suspend the use, supply and sale of Avacopan Vifor (previously Tavneos) to new patients from 1 September 2026, after concluding that data integrity problems in the pivotal trial mean the study can no longer demonstrate efficacy. The drug, authorised on 6 May 2022 with rituximab or cyclophosphamide for severe, active GPA or MPA in adults, will be supplied only to existing patients during a six-month managed withdrawal, with the UK marketing authorisation to be revoked on 1 March 2027. Clinicians should not start new patients on the medicine and should review current patients for alternative treatments.

    Why it matters: UK regulator suspends and plans to revoke a vasculitis drug's authorisation over unreliable pivotal trial data.

Aug 31Mon
  1. statnews.com64

    STAT+: FDA approves Protagonist and Takeda’s drug for rare blood cancer

    The FDA approved rusfertide, developed by Protagonist Therapeutics and to be sold by Takeda as Mimrylo, for polycythemia vera, a chronic blood cancer in which overproduction of red blood cells raises the risk of heart attacks, strokes and blood clots. Mimrylo is a weekly injection described as a new kind of treatment for the rare, slow-growing cancer.

    Why it matters: FDA approval of a first-in-class therapy for a rare blood cancer from Protagonist and Takeda.

Aug 29Sat
  1. fiercepharma.com55

    Takeda bolsters blood cancer portfolio with FDA nod for Mimrylo in polycythemia vera

    The FDA has approved Takeda's Mimrylo (rusfertide) for polycythemia vera, a nonmalignant rare blood cancer. Mimrylo brings a new mechanism of action to the indication and adds to CEO Julie Kim's record of regulatory wins since taking the role.

    Why it matters: FDA approval of a new-mechanism therapy for a rare blood cancer expands Takeda's oncology portfolio.

  2. fda.gov66

    FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder

    The FDA approved Takeda Pharmaceuticals' Mimrylo (rusfertide) for adults with polycythemia vera whose disease is not adequately controlled by existing therapies. It is the first approved treatment for the disorder that mimics hepcidin, limiting iron available for red blood cell production. In the phase 3 VERIFY trial of 293 adults, 76.9% on Mimrylo needed no phlebotomies over 32 weeks versus 32.9% on placebo; common adverse reactions were injection site reactions and anemia. Approval followed priority review.

    Why it matters: First-in-class hepcidin mimic approved for polycythemia vera based on phase 3 VERIFY results.

Aug 28Fri
  1. statnews.com59

    STAT+: FDA approves Roivant therapy for rare autoimmune disease

    The FDA has approved brepocitinib, brand name Lisraya, from Roivant and its subsidiary Priovant, for dermatomyositis, a rare autoimmune disease marked by muscle weakness and a painful skin rash. The once-daily pill affects a U.S. patient population of 40,000 to 70,000 and offers an alternative to high-dose steroids and other immune-suppressing drugs.

    Why it matters: FDA approval of a new oral therapy for a rare autoimmune disease with no tailored standard of care.

  2. fda.gov69

    FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults

    The FDA has approved Priovant Therapeutics' Lisraya (brepocitinib) tablets, the first oral treatment indicated for dermatomyositis in adults. The once-daily JAK/TYK2 inhibitor was supported by a phase 3 placebo-controlled study of 241 adults, in which the 30 mg dose produced a higher average Total Improvement Score at week 52 and allowed more patients to cut corticosteroid use. It carries a boxed warning for serious infections, mortality, malignancies, cardiovascular events and thrombosis, and was granted Orphan Drug and Priority Review designations.

    Why it matters: First FDA-approved oral therapy for dermatomyositis, a rare disease with few treatment options.

Aug 25Tue
Aug 20Thu
  1. fiercepharma.com82

    Ultragenyx, after FDA speed bump, lands 1st gene therapy nod with green light in glycogen storage disease

    The FDA granted accelerated approval to Ultragenyx's AAV gene therapy pariglasgene brecaparvovec-opnr, brand name Genglycos, for adults and children over 8 with glycogen storage disease type Ia. In the phase 3 GlucoGene study, the one-time AAV8 therapy cut daily cornstarch intake by a mean 31% from baseline versus placebo over 48 weeks. Ultragenyx, which also received a priority review voucher, must provide two years of safety and efficacy data on 50 treated and 20 control patients; it awaits a Sept. 19 decision on UX1111.

    Why it matters: First FDA gene therapy approval for Ultragenyx in an ultrarare disease, with a launch and confirmatory commitments following.

  2. fda.gov69

    FDA Approves First Therapy for Patients aged 8 years and older with Glycogen Storage Disease Type Ia

    The FDA granted accelerated approval to Ultragenyx Pharmaceutical's Genglycos (pariglasgene brecaparvovec-opnr), a one-time AAV8 gene therapy and the first approved treatment for glycogen storage disease type Ia in patients aged 8 and older. In a 48-week randomized placebo-controlled study, patients achieved a statistically significant 31% mean reduction in daily cornstarch intake, the primary endpoint. The manufacturer must complete additional trials to confirm effectiveness, and the label warns of anaphylaxis, liver toxicity, adrenal insufficiency and tumorigenicity risk.

    Why it matters: FDA cleared the first therapy for glycogen storage disease type Ia under the accelerated pathway.

  3. statnews.com84

    STAT+: Regeneron drug for disease that causes dangerous bone growth earns FDA approval

    The FDA has approved Regeneron Pharmaceuticals' Pasatru for fibrodysplasia ossificans progressiva, an ultra-rare disease in which bone grows where it should not. The approval caps a three-decade effort and follows a pivotal trial in which the medicine drastically cut the risk of new bone formation. Patients with FOP typically rely on wheelchairs by age 25, and investigators hope Pasatru can help maintain mobility.

    Why it matters: First FDA approval of a treatment for FOP after a three-decade development effort.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org